Helen Livesey
Research Subjects
Research Interests
Helen Livesey has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Arrash Yassaee
School of Public Health, Imperial College London, London, United Kingdom
2 shared publications - Damian Roland
Sapphire Group, Health Sciences, University of Leicester, Leicester, UK
2 shared publications - Genevieve Southgate
Southampton Children’s Hospital, University Hospital Southampton NHS Foundation Trust, Tremona Road, SO16 6YD, Southampton, UK 1
2 shared publications - Kate Pryde
Department of General Paediatrics, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Matthew James Harmer
Southampton Children's Hospital, Southampton, UK; University of Southampton, Southampton, UK
2 shared publications Ailsa Rose
University of Leeds
1 shared publication
Latest Publications
- Open Access
- 12 June 2023
- Published by Springer Nature in Research Square
A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes.
Cyclin D2 (CCND2) stabilisation underpins a range of macrocephaly-associated disorders through mutation of CCND2, or activating mutations in upstream genes encoding PI3K-AKT pathway components. Here we describe three individuals with overlapping macrocephaly-associated phenotypes who carry the same recurrent de novo p.Arg60Gln variant in Myc-associated factor X (MAX). The mutation, located in the b-HLH-LZ domain, causes increased levels of CCND2 through increased transcription, and not stabilisation of CCND2. We show the purified b-HLH-LZ domain of MAXR60Q (Max*R60Q) binds its target E-Box sequence with a lower apparent affinity. This leads to a more efficient heterodimerization with c-Myc resulting in an increase in transcriptional activity of c-Myc in patients carrying this mutation. The recent development of Omomyc-CPP, a cell penetrating b-HLH-LZ domain c-Myc inhibitor, provides a possible therapeutic option for MAXR60Q patients, and others carrying similar germline mutations resulting in dysregulated transcriptional c-Myc activity.
- 12 June 2023
- Published by Springer Nature in Research Square
Open AccessA recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes.
Cyclin D2 (CCND2) stabilisation underpins a range of macrocephaly-associated disorders through mutation of CCND2, or activating mutations in upstream genes encoding PI3K-AKT pathway components. Here we describe three individuals with overlapping macrocephaly-associated phenotypes who carry the same recurrent de novo p.Arg60Gln variant in Myc-associated factor X (MAX). The mutation, located in the b-HLH-LZ domain, causes increased levels of CCND2 through increased transcription, and not stabilisation of CCND2. We show the purified b-HLH-LZ domain of MAXR60Q (Max*R60Q) binds its target E-Box sequence with a lower apparent affinity. This leads to a more efficient heterodimerization with c-Myc resulting in an increase in transcriptional activity of c-Myc in patients carrying this mutation. The recent development of Omomyc-CPP, a cell penetrating b-HLH-LZ domain c-Myc inhibitor, provides a possible therapeutic option for MAXR60Q patients, and others carrying similar germline mutations resulting in dysregulated transcriptional c-Myc activity.
- Open Access
- 26 October 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (10) , e38267
Use of Telemedicine in Pediatric Services for 4 Representative Clinical Conditions: Scoping Review
Background: Telemedicine is becoming routine in health care. Postpandemic, a universal return to face-to-face consultations may risk a loss of some of the advantages of telemedicine. However, rapid implementation and adoption without robust evaluation of usability, efficacy, and effectiveness could potentially lead to suboptimal health outcomes and downstream challenges to providers. Objective: This review assesses telemedicine interventions against international guidance and sufficiency of evidence to support postpandemic utilization in pediatric settings. Methods: This scoping review was performed following searches on PubMed, Embase, and CINAHL databases on April 15, 2021, and May 31, 2022, and examined studies focused on telemedicine, remote consultation, video call, or remote patient monitoring in children (0-18 years) receiving outpatient care for diabetes, asthma, epilepsy, or renal disease. Exclusion criteria included studies published before 2011 as the technologies used have likely been improved or replaced, studies in adult populations or where it was not possible to disaggregate data for participants younger than 18 years as the focus of the review was on pediatric care, and studies not published in English. Data were extracted by 4 authors, and the data were corroborated by a second reviewer. Studies were examined for feasibility and usability, clinical and process outcomes, and cost-effectiveness. Results: Of the 3158 studies identified, 56 were suitable for final inclusion and analysis. Data on feasibility or usability of interventions (48 studies) were overwhelmingly positive in support of telemedicine interventions, with common themes including convenience, perceived cost savings, and ease of use. However, use in preference to usual care was rarely explored. Clinical and process outcome data (31 studies) were mostly positive. Across all studies, there was limited measurement of standardized clinical outcomes, although these were more commonly reported in asthma (peak flow) and diabetes (glycated hemoglobin [HbA1c]). Implementation science data generally supported cost-effectiveness of telemedicine with a reduction of health care costs. Conclusions: There is promising evidence supporting telemedicine in pediatric settings. However, there is a lack of evaluation of telemedicine in comparison with usual outpatient care for noninferiority of clinical outcomes, and this review highlights the need for a more standardized approach to evaluation of digital interventions.
- 26 October 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (10) , e38267
Open AccessUse of Telemedicine in Pediatric Services for 4 Representative Clinical Conditions: Scoping Review
Background: Telemedicine is becoming routine in health care. Postpandemic, a universal return to face-to-face consultations may risk a loss of some of the advantages of telemedicine. However, rapid implementation and adoption without robust evaluation of usability, efficacy, and effectiveness could potentially lead to suboptimal health outcomes and downstream challenges to providers. Objective: This review assesses telemedicine interventions against international guidance and sufficiency of evidence to support postpandemic utilization in pediatric settings. Methods: This scoping review was performed following searches on PubMed, Embase, and CINAHL databases on April 15, 2021, and May 31, 2022, and examined studies focused on telemedicine, remote consultation, video call, or remote patient monitoring in children (0-18 years) receiving outpatient care for diabetes, asthma, epilepsy, or renal disease. Exclusion criteria included studies published before 2011 as the technologies used have likely been improved or replaced, studies in adult populations or where it was not possible to disaggregate data for participants younger than 18 years as the focus of the review was on pediatric care, and studies not published in English. Data were extracted by 4 authors, and the data were corroborated by a second reviewer. Studies were examined for feasibility and usability, clinical and process outcomes, and cost-effectiveness. Results: Of the 3158 studies identified, 56 were suitable for final inclusion and analysis. Data on feasibility or usability of interventions (48 studies) were overwhelmingly positive in support of telemedicine interventions, with common themes including convenience, perceived cost savings, and ease of use. However, use in preference to usual care was rarely explored. Clinical and process outcome data (31 studies) were mostly positive. Across all studies, there was limited measurement of standardized clinical outcomes, although these were more commonly reported in asthma (peak flow) and diabetes (glycated hemoglobin [HbA1c]). Implementation science data generally supported cost-effectiveness of telemedicine with a reduction of health care costs. Conclusions: There is promising evidence supporting telemedicine in pediatric settings. However, there is a lack of evaluation of telemedicine in comparison with usual outpatient care for noninferiority of clinical outcomes, and this review highlights the need for a more standardized approach to evaluation of digital interventions.
- Open Access
- 15 April 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (5) , 766-767
SAFEGUARDING SHOULD BE A KEY OUTCOME MEASURE WHEN EVALUATING VIDEO CONSULTATIONS IN PAEDIATRICS
- 15 April 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (5) , 766-767
Open AccessSAFEGUARDING SHOULD BE A KEY OUTCOME MEASURE WHEN EVALUATING VIDEO CONSULTATIONS IN PAEDIATRICS